Fresh Equities




Looking for more information?

Contact our responsive and friendly client services team any time.




Raising capital in the Biotech and Health Sector

Biotech and health companies form a key part of the ASX and are focused on developing the next generation of medicine and pharmaceuticals. These businesses may range from early stage developers seeking to validate their discovery, through to large multi-nationals with a portfolio of proven therapies and products.

Interested in capital raises from companies in the Biotech sector?

Become a client with Fresh Equities today to gain access to future raises.

What does the biotech sector look like in 2020

Pre-clinical biotech in 2020

For many early stage or pre-clinical biotech/health companies, investor capital would go towards preliminary studies around safety, synthesis among other ex vitro tests. The goal here is to provide all the necessary data and information to support an eventual clinical trial.

Clinical and post-clinical biotech in 2020

Once a company has an adequate level of confidence and data for their drug candidate, they may choose to advance to clinical trials. These clinical trials typically consist of 3 phases, each increasing in regulatory, safety, and technical requirements. These may involve both human, and non-human test subjects and can take last several years to complete. This is commonly the riskiest part of the biotech development cycle, but successful results may lead to favorable corporate activity.


Following the onset of the COVID-19 pandemic in 2020, there has been substantial interest in developing related treatments and vaccines. This has seen a substantial number of companies either develop new drugs or re-purpose existing treatments for potential coronavirus applications.

Approval phase

When a company successfully trails their product, they will then move to seek regulatory approval and ultimately marketing. This completes the company’s transition to a revenue generating business. At this step, the company may choose to conduct post-marketing surveillance, commonly known as stage 4 trails to monitor for long term effects.

Fresh Equities
App StorePlay Store

Copyright © 2024 Fresh Equities. All rights reserved. ACN 619 657 028. CAR: 001267539 of AFSL: 471379.